Tower Research Capital LLC (TRC) - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H203. A total of 23 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2022$3,000
-40.0%
4,508
-12.6%
0.00%
Q2 2022$5,000
+150.0%
5,156
+307.6%
0.00%
Q1 2022$2,000
-81.8%
1,265
-36.7%
0.00%
Q3 2021$11,000
-81.4%
1,997
-81.6%
0.00%
-100.0%
Q1 2021$59,000
+15.7%
10,871
+2.8%
0.00%
-50.0%
Q4 2020$51,00010,5720.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
Samjo Capital LLC 381,713$1,828,0001.56%
Cowen Prime Services LLC 441,918$2,117,0000.94%
Nantahala Capital Management 363,622$1,742,0000.05%
GSA CAPITAL PARTNERS LLP 45,221$217,0000.04%
HighMark Wealth Management LLC 6,666$32,0000.03%
Tower Research Capital LLC (TRC) 10,572$51,0000.00%
Qube Research & Technologies Ltd 12,034$58,0000.00%
Squarepoint Ops LLC 25,597$123,0000.00%
Ironwood Financial, llc 103$00.00%
OSAIC HOLDINGS, INC. 24$00.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders